Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection

Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection Amir Eftekhari Milani, Amin Arasteh, Zahra Saeedi-Maleki, Fariborz Brumandpur This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3979739/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 10 You are reading this latest preprint version Abstract Background Retinopathy of prematurity (ROP) is a proliferative disorder of the developing retina. Intravitreal bevacizumab injection (IVB) is an emerging treatment for ROP is one of the treatments for ROP has many benefits. The present study aimed to determine and evaluate the risk factors for ROP recurrence following IVB injection. Materials and method In this retrospective study, 98 eyes of 49 infants with ROP who had received IVB injections as the primary treatment for type 1 ROP are included. Results Fifty-four eyes (55.1%) had Aggressive posterior retinopathy of prematurity (APROP), and forty-four (44.9%) had Stage III Plus ROP in Zone II. ROP recurred in 13 eyes (13.26%) of 8 infants. The mean period between IVB and the ROP recurrence was 8.08 (95% CI:5.32–10.83) weeks. The infants who had ROP recurrence had lower birth weight (P value = 0.002), lower postmenstrual age at IVB injection (P value = 0.001), lower IVB injection gap period from birth (P value = 0.044), higher oxygen therapy requirement rate after IVB injection (P value < 0.001, OR:19.0) and higher oxygen therapy duration (P value = 0.006). The ROP severity, gestational age at birth, and diet were not statistically different between the recurrence and complete regression groups. Out of 13 eyes treated with laser photocoagulation because of ROP relapse, macula dragging occurred in one eye, and all the cases met the complete regression. Conclusion Low birth weight and oxygen therapy are the most important risk factors for ROP relapse, which requires meticulous oxygen treatment guidelines for premature infants. Bevacizumab Recurrence Retinopathy of prematurity Risk factors Figures Figure 1 Figure 2 Introduction Retinopathy of prematurity (ROP) is one of the major causes of potentially avoidable blindness among infants worldwide ( 1 ). Blood levels of oxygen and their fluctuations have a prominent role in the physiopathology of ROP in preterm neonates by affecting endothelial growth factor secretion. Coincidence of other morbidities such as respiratory failure, sepsis, poor nutrition and weight gain, and blood sugar fluctuations could exacerbate the risk of ROP in premature infants ( 2 ). The incidence of ROP is constantly increasing as more immature infants survive due to the improvement of neonatal care ( 3 ). Laser photocoagulation is currently the gold standard treatment for ROP but might restrict the visual field and contribute to myopia development ( 4 , 5 ). The BEAT-ROP demonstrated a beneficial effect for intravitreal Bevacizumab (IVB) vs. laser in treating Zone I, Stage 3 + ROP ( 6 ). IVB has also been used safely for the treatment of aggressive posterior ROP ( 7 ). IVB treatment could rapidly lead to the regression of vascular abnormality, especially in eyes with miotic pupils, and also lower the incidence of induced high myopia in type 1 ROP, compared with laser ablation. However, recurrence remains a major concern in the administration of IVB ( 8 ). Different risk factors have been related to ROP recurrence, such as Zone I ROP, early need for treatment, and low Apgar score ( 9 ). In this study, we aimed to retrospectively investigate children who received IVB as the primary treatment of ROP to compare some risk factors between those with and without ROP recurrence and complications after ROP recurrence treatment. Materials and method Patients and examinations: This retrospective study investigated ROP recurrence risk factors among those who received IVB because of ROP type 1 during one year (September 2022 to September 2023) in Nikookari Hospital, Tabriz, Iran. This center is the referral ROP center in the northwest of Iran. In this study, 98 eyes of 49 infants with ROP who had received IVB injections as the primary treatment are included. The exclusion criteria were IVB complications such as endophthalmitis and cataract formation. We did not have any infants with exclusion criteria. All of the patients had regular follow up at scheduled times. Recurrence was defined as the redevelopment of plus disease, pathological new vessels, or elevated ridge following a complete regression of ROP after IVB injection. We compared the following risk factors between those with and without ROP recurrence: birth gestational age (weeks), postmenstrual age at IVB injection time (days), IVB injection gap period from birth (days), birth body weight (grams), any history of oxygen therapy after IVB injection, mean oxygen therapy period after IVB injection (days), ROP Stage, and diet (breastfeeding, powdered milk or mixed). A retina subspecialist examined all infants after pupillary dilation with topical tropicamide 0.8%. Indirect funduscopy by pan-retinal Volk lens (Mentor, Ohio 44060, US) was used for retinal examination. The same physician examined all patients during follow-up visits and the IVB injections. The IVB was injected on the same day of the examination for type 1 ROP. Any ROP stage with plus disease in zone I, stage 3 ROP in zone I, and stage 2 or 3 ROP with plus disease in zone II are classified as type 1 ROP ( 10 ). In the case of ROP recurrence, the same physician applied retinal laser photocoagulation. Intravitreal injections: The parents of all the neonates were informed about the IVB injection procedure and its possible side effects and complications. Then, written informed consent forms were taken before the procedure. All the neonates received intravitreal Bevacizumab (0.25 mg/0.01 mL) injection with a gauge-30 needle inserted at 0.5 to 1.0 mm distance from limbus supra-temporally under sedation and topical anesthesia. Ethical considerations: The study was approved by the medical research ethics committee at Tabriz University of the Medical Sciences with an approval code of IR.TBZMED.REC.1401.800. As mentioned above, all the procedures were applied after the parents' informed consent was taken. Statistical analysis: All the statistical analysis in this study was performed using IBM SPSS Statistics 27.0, and the Kaplan-Meier curves were depicted by GraphPad Prism 10.0. The distribution of the quantitative data was examined by the Kolmogorov-Smirnov test and histograms. The normally distributed variables were analyzed by parametric tests such as the student's T-test, and the other data were analyzed by non-parametric tests such as Mann-Whitney U. The categorical variables were analyzed by Chi-square and Fisher-Freeman-Halton Exact Test. The alpha error in this study is considered 0.05, and p-values lower than 0.05 are considered statistically significant. Results Recurrence rate and ROP severity: 98 eyes of 49 infants with ROP who had received intravitreal Bevacizumab are included in our study. 55.1% of the ROP cases had APROP, and 44.9% had Stage III Plus ROP in Zone II. Despite the intravitreal injection, the ROP recurred in 13 eyes (13.26%) of 8 infants. The mean period between the IVB injection and the ROP recurrence was 8.08 (95%CI:5.32–10.83) weeks. Figure 1 shows the Kaplan-Meier curve of ROP recurrence after IVB injection. All the eyes with ROP recurrence received laser photocoagulation therapy, and 12 achieved anatomic improvements and ROP regression without complications. However, in one eye, macular dragging happened after laser therapy and ROP regression. 76.9% of the infants with ROP recurrence had APROP before IVB injection; on the other hand, the prevalence of the APROP in the infants with complete ROP regression was 51.7%. Although the recurrence rate in the APROP group was 18.51% compared to 6.81% in the zone II ROPs, this difference was not statistically significant regarding the Chi-Square test (p-value = 0.089). The remaining infants in both groups had Stage III Plus ROP in Zone II. Gestational age and birth body weight: The median gestational age of the infants with the ROP recurrence was 26 (the interquartile range (IQR): 26.00–29.00) weeks at birth. It was 29 (IQR: 27.25-30.00) weeks for the infants without the ROP recurrence. According to the Independent-Samples Mann-Whitney U Test, the two groups have no statistically significant difference (p-value = 0.072). On the other hand, the ROP recurrence group received the IVB injection at the median postmenstrual age of 232 (IQR: 229.50-244.50) days compared to 251 (IQR: 245.00-257.00) days in the regressed eyes, which is a statistically significant difference (p-value = 0.001). The ROP recurrence cases received the IVB injection in younger gestational ages compared to the complete regression cases. Also, when the time gap between the birth and the IVB injection was compared, results showed a significantly shorter gap period for the ROP recurrence cases. Completely regressed ROP cases received the IVB injection in a median of 50 (IQR: 40.00–60.00) days from birth, while the recurrence cases received 30 (IQR: 30.00-58.50) days after birth (p-value = 0.044). In addition, the two groups significantly differed regarding the birth body weight. The median weight for infants with the ROP recurrence was 1000 (IQR: 732–1000) grams versus 1100 (IQR: 1000–1350) grams in the other group (p-value = 0.002). The infants who achieved the ROP regression without recurrence after the IVB injection had higher birth body weights. Supplemental oxygen therapy: 10.58% of completely regressed ROP cases needed supplement oxygen therapy after the IVB injection compared to 69.23% of those in the ROP recurrence group. The difference between the two groups is statistically significant (p-value < 0.001). The odds ratio for supplemental oxygen therapy after IVB injection is 19.0 (95%CI: 4.8–74.4). While the prevalence of supplemental oxygen therapy was higher in the ROP recurrence group, there was also a significant difference in the mean oxygen therapy period between infants who received oxygen in the two groups (p-value = 0.006). The mean period of oxygen therapy after the IVB injection was 9.0 (95%CI: 6.5–11.4) days in the ROP recurrence cases and 5.0 (95%CI: 5.00–5.00) in the complete regression group. The ROP recurrence cases, on average, received supplemental oxygen for 4.0 (95%CI: 1.5–6.4) days more than the other group after the IVB injection. Figure 2 shows the Kaplan-Meier curve of ROP recurrence in two groups regarding the need for supplemental oxygen therapy after IVB injection. Diet: The two groups had no significant difference in the infants' diet. 51.8% of wholly regressed ROPs received a combination of maternal and powdered milk, and 61.6% in the ROP recurrence group had the same diet (p-value = 0.097). Neither the maternal nor powdered milk was associated with the ROP recurrence (p-value = 0.321 and p-value = 0.064, respectively). The ocular and demographic characteristics of the infants are available in Table 1 in more detail. Table 1 Ocular and demographic characteristics of infants with ROP in two groups of complete regression and recurrence after IVB injection. T: Students' T-test, M: Mann-Whitney U, C: Chi-square, F: Fisher-Freeman-Halton Exact Test ROP Recurrence (n:13) ROP Regression (n:85) p-value Birth gestational age (weeks) 26 (IQR: 26.00–29.00) 29 (IQR: 27.25-30.00) 0.072 M Postmenstrual age at IVB injection (days) 232 (IQR: 229.50-244.50) 251 (IQR: 245.00-257.00) 0.001 M IVB injection gap period from birth (days) 30 (IQR: 30.00-58.50) 50 (IQR: 40.00–60.00) 0.044 M Birth body weight (grams) 1000 (IQR: 732–1000) 1100 (IQR: 1000–1350) 0.002 M Oxygen therapy after IVB injection (n) 9 (69.23%) 9 (10.58%) < 0.001 C Mean oxygen therapy period (days) 9.0 (95%CI: 6.5–11.4) 5.0 (95%CI: 5.00–5.00) 0.006 T Stage (n) APROP 10 (76.9%) 44 (51.7%) 0.089 C Z(II) S(III) plus 3 (23.1%) 41 (48.3%) Diet (n) Maternal 0 (0%) 20 (23.5%) 0.097 F Powdered 5 (38.4%) 21 (24.7%) Mixed 8 (61.6%) 44 (51.8%) Discussion The physiological process of human embryonic retinal vascularization consists of vasculogenesis and angiogenesis. Through vasculogenesis, blood vessels are generated by the endothelial cells' differentiation from their progenitors. This process takes place between the 12th and 21st week of gestational age. Angiogenesis is the process that leads to the formation of the superficial plexus. During angiogenesis, the retinal capillary plexus is generated from the optic nerve retinal vessels, branched and elongated towards the peripheral retina. These new vessels reach the nasal and temporal periphery at 32 and 36–40 weeks of gestational age, respectively ( 10 ). ROP is a vasoproliferative disease caused by Vascular endothelial growth factor (VEGF) production due to retinal ischemia. IVB has been suggested as a treatment for ROP in the presence of aggressive posterior ROP, miotic pupil, or media opacity. Its advantages over laser therapy are availability, a simple technique of injection, and the preservation of the visual field. It has some disadvantages compared to laser therapy, including endophthalmitis, cataract formation, and a higher recurrence rate, especially after a more extended period ( 9 ). The major risk factors for ROP are prematurity (low gestational age and birth weight) and supplemental Oxygen therapy. More advanced neonatal care and specialized hospitals could reduce the ROP incidence rate, as small hospital studies compared with tertiary referral hospitals approve of it ( 11 ). When the gestational age is lower, the area of the ischemic retina is more extensive. As a result, the concentration of VEGF in the vitreous cavity would be higher, so the probability of type 1 ROP requiring treatment would be higher ( 12 ). ROP recurrence is the redevelopment of plus disease, pathological new vessels, or elevated ridge following a complete regression of ROP following treatment ( 13 ). The recurrence rate in our study was 13.26%, which was relatively lower than in similar studies. A study comparing laser photocoagulation and intravitreal Ranibizumab injection showed an 18.3% recurrence rate in the Ranibizumab group. However, the mean interval between the injection and recurrence was similar (8.08 vs. 9.3 weeks) ( 14 ). On the other hand, another study showed a much lower recurrence rate (4.04%) after IVB injection in ROP cases. This lower recurrence rate might be related to the lower prevalence of Zone I ROP (21.6%) in the sample size ( 8 ). In our study, low birth weight was a risk factor for ROP recurrence. However, lower gestational age was not statistically significant (the median gestational age was 26 weeks in the group with ROP recurrence compared to 29 weeks in those without recurrence). This statistically insignificant difference can be due to the study's low recurrence rate and small sample size. Most studies have confirmed that lower gestational age and weight are risk factors for ROP and its recurrence ( 7 – 9 ). However, logistic regression in a large study revealed that the Gestational age (GA) and Birth weight are not independent risk factors for the recurrence after Ranibizumab ( 14 ). The possible relationship between lower GA and Birth weight with ROP recurrence can be explained by more immature retinal vasculature, which leads to a larger area of ischemic retina, as mentioned above. Although GA was not a statistically significant risk factor for recurrence in our study, the lower postmenstrual age at IVB injection was associated with ROP recurrence. The Iwahashi et al showed a higher rate of recurrence in neonates receiving anti-VEGF threpy earlier than 35-week of postmenstrual age ( 15 ). Supplemental oxygen therapy has been described as a risk factor for ROP development ( 2 , 11 , 16 ). In this study, we investigated the role of oxygen therapy after IVB injection. The number of children who received Oxygen after IVB injection and the duration of oxygen therapy were higher in the group with ROP recurrence. Similar to our study, the study by Ling et al. showed that oxygen therapy after IVB injection or intravitreal ranibizumab injection was associated with higher ROP relapse ( 9 ). It has been declared that O 2 saturation fluctuations are more related to higher oxidative stress and ROP occurrence than steady prolonged hyperoxia ( 17 ). So, infants who need oxygen therapy even after IVB injection may have more unstable respiratory and metabolic conditions, leading to more oxidative stress, which induces ROP recurrence. Besides, we have to take into account that these children are hospitalized due to respiratory problems or other systemic conditions that can worsen retinal hypoxia or ischemia. Premature infants are more prone to other exacerbating conditions, such as infections, and may have more severe forms of retinopathy due to the lower compliance of anti-oxidant metabolic pathways ( 8 ). With lower oxygen saturation, the rate of mortality increases; with higher oxygen saturation, the rate of ROP increases ( 18 ). So, it is hard to determine which oxygen saturation level suits these patients. Similar to Ling et al. study ( 9 ), those infants who received IVB injection sooner after birth had a higher probability of ROP recurrence (the median of 30 days in those with ROP recurrence versus 50 days in those without relapse). This difference shows that the imbalance between angiogenic and anti-angiogenic agents occurs at a shorter period in these children, leading to the development of type 1 ROP. So, the probability of reaching this unbalanced state in the future after IVB injection is higher among these infants. Recent studies hypothesized that lower Insulin-like growth factor-1 (IGF-1) levels at birth could be related to the ROP occurrence, and infants' nutrition could alter the IGF-1 levels ( 19 ). In addition, a systematic review demonstrated a protective role for human milk intake against the ROP and its severe forms ( 20 ). We aimed to find any possible association between the infants' diet type and ROP recurrence, which is not addressed well in the literature; however, we did not find any significant relationship. Conclusion ROP is the most common cause of visual impairment among infants. So, the most critical point in ROP management is preventing severe forms (type 1) that require treatment by improving neonatal care and well-established ophthalmic screenings for preterm infants. Although IVB injection could be a suitable replacement for laser photocoagulation in the ROP treatment, the recurrence after treatment should be considered, and infants should be monitored closely, especially until ten weeks, when most recurrences occur. Infants with lower Birth weight, an earlier need for IVB injection, and those who need supplemental oxygen for a more extended period should be considered at high risk for recurrence. Besides, a collaboration between neonatologists and ophthalmologists could lower the recurrence rate by minimizing post-IVB oxygen therapy. Abbreviations ROP Retinopathy of prematurity IVB Intravitreal bevacizumab injection APROP Aggressive posterior retinopathy of prematurity VEGF Vascular endothelial growth factor GA Gestational age IGF-1 Insulin-like growth factor-1 Declarations Author information: Authors and Affiliations. Department of Ophthalmology, Nikookari Eye Hospital,Tabriz University of Medical Sciences, Tabriz, Iran: Amir Eftekhari Milani, Amin Arasteh, Zahra Saeedi-Maleki, Fariborz Brumandpur Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran: Amin Arasteh Ethics approval and consent to participate The study was approved by the medical research ethics committee at Tabriz University of the Medical Sciences with an approval code of IR.TBZMED.REC.1401.800. All the procedures were applied after the parents' informed consent was taken. The study was conducted in accordance with the Declaration of Helsinki, good clinical practices, and relevant regulatory guidelines. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests Funding: No fund Author Contribution Experimental design: AEM, FB.Data collection and analysis: AEM, AA.Manuscript drafting and revision: FB, ZSM, AAAll authors reviewed the manuscript. Acknowledgments: Not applicable Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. References Soll RF. Treatment of Retinopathy of Prematurity: Moving Forward With Uncertainty. JAMA. 2022;328(4):332–3. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(1):35–49. Pertl L, Steinwender G, Mayer C, Hausberger S, Pöschl EM, Wackernagel W, et al. A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE. 2015;10(6):e0129383. McLoone E, O'Keefe M, McLoone S, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44(3):170–3. Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131(8):1099–101. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal Bevacizumab for stage 3 + retinopathy of prematurity. N Engl J Med. 2011;364(7):603–15. Eftekhari Milani A, Hassanpoor N, Mousavi Mirkala M, Taheri A, Golizade A, Niyousha MR. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity. Int Ophthalmol. 2020;40(2):477–82. Fadakar K, Mehrabi Bahar M, Riazi-Esfahani H, Azarkish A, Farahani AD, Heidari M, et al. Intravitreal Bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence. Int Ophthalmol. 2022;42(7):2017–28. Ling KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina Phila Pa. 2020;40(9):1793–803. Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515–26. Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of Prematurity: A Review of Risk Factors and their Clinical Significance. Surv Ophthalmol. 2018;63(5):618–37. Sonmez K, Drenser KA, Capone A, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophtha. 2008;115(6):1065–70. Martínez-Castellanos MA, González-H León A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):767–72. Cao JK, Han T, Tang HY, Zhang S, Wang ZH, Feng ZC, et al. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmol. 2023;23(1):137. Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, et al. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina. 2021;41(11):2261. Lyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, et al. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors. Invest Ophthalmol Vis Sci. 2017;58(3):1719–25. Fevereiro-Martins M, Marques-Neves C, Guimarães H, Bicho M. Retinopathy of prematurity: A review of pathophysiology and signaling pathways. Surv Ophthalmol. 2023;68(2):175–210. Hartnett ME, Lane RH. Effects of Oxygen on the development and severity of retinopathy of prematurity. J AAPOS. 2013;17(3):229–34. Woods J, Biswas S. Retinopathy of prematurity: from oxygen management to molecular manipulation. Mol Cell Pediatr. 2023;10(1):12. Bharwani SK, Green BF, Pezzullo JC, Bharwani SS, Bharwani SS, Dhanireddy R. Systematic review and meta-analysis of human milk intake and retinopathy of prematurity: a significant update. J Perinatol. 2016;36(11):913–20. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 14 May, 2024 Reviews received at journal 09 May, 2024 Reviews received at journal 07 May, 2024 Reviewers agreed at journal 30 Apr, 2024 Reviewers agreed at journal 30 Apr, 2024 Reviewers invited by journal 30 Apr, 2024 Editor invited by journal 27 Feb, 2024 Editor assigned by journal 27 Feb, 2024 Submission checks completed at journal 27 Feb, 2024 First submitted to journal 22 Feb, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3979739","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":275216612,"identity":"4a2d6a0c-b6a2-435e-bec8-dd2dab0c3f94","order_by":0,"name":"Amir Eftekhari Milani","email":"","orcid":"","institution":"Tabriz University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Amir","middleName":"Eftekhari","lastName":"Milani","suffix":""},{"id":275216613,"identity":"b13bfb61-c584-40f8-94b5-874ca858fabb","order_by":1,"name":"Amin Arasteh","email":"","orcid":"","institution":"Tabriz University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Amin","middleName":"","lastName":"Arasteh","suffix":""},{"id":275216614,"identity":"43d5ddfb-905b-4dc4-a58a-6a8a819bef80","order_by":2,"name":"Zahra Saeedi-Maleki","email":"","orcid":"","institution":"Tabriz University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Zahra","middleName":"","lastName":"Saeedi-Maleki","suffix":""},{"id":275216615,"identity":"64ca6184-d8e6-4dd6-b359-30da356782d2","order_by":3,"name":"Fariborz Brumandpur","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA5ElEQVRIiWNgGAWjYBAC9gYGhsNglgQD4wMgxcNHSAvPAYQWZgOQABsxWpihWtgkQDRhLexnHx4uqLhnzyDd+6zya46dDBsD88NHN/Bp4Uk3ODzjTDEzg8xxs9uy25KBDmMzNs7Bo8WeIY3hMG9bAhuDRBrbbcltzEAtPGzS+LTw8D8Da+EBaSmW3FZPhBYJiC0SIC2MH7cdJkYL0JYZZxIM2GSOMUszbjvOw8ZMwC88/GnMnwsqEuz5pdsYP/7cVm3Pz9788DE+LXAAig5mHhCLmRjlMMD4gxTVo2AUjIJRMGIAAD3WOpuG1VvtAAAAAElFTkSuQmCC","orcid":"","institution":"Tabriz University of Medical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Fariborz","middleName":"","lastName":"Brumandpur","suffix":""}],"badges":[],"createdAt":"2024-02-22 20:30:21","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3979739/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3979739/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":51820336,"identity":"09c1c157-af19-45c9-a7a5-298367b503a2","added_by":"auto","created_at":"2024-02-29 16:00:21","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":66479,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Meier recurrence-free probability curve of ROP received IVB. The blue line demonstrates the probability of recurrence-free condition, and the green lines demonstrate the 95% confidence interval.\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-3979739/v1/de615cd6f1443669610773b5.jpeg"},{"id":51820337,"identity":"8366d77c-a50a-4182-92ae-edfb5f3f990a","added_by":"auto","created_at":"2024-02-29 16:00:21","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":86028,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Mier curve of ROP recurrence in two groups regarding the need for supplemental oxygen therapy after IVB injection. The red points and line demonstrate the ROP recurrence probability in the group receiving supplemental oxygen therapy, and the blue line shows the other group. Bars show the 95% confidence interval. The group in need of supplemental oxygen therapy after IVB injection has a significantly higher risk of ROP recurrence.\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-3979739/v1/83d3b232a0ac8d241936097a.jpeg"},{"id":51821072,"identity":"22a40316-0764-4d02-8803-d7d408c9f3b1","added_by":"auto","created_at":"2024-02-29 16:08:21","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":412931,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3979739/v1/b5f1a7df-301c-4dcd-bef3-d409a61a29a5.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection","fulltext":[{"header":"Introduction","content":"\u003cp\u003eRetinopathy of prematurity (ROP) is one of the major causes of potentially avoidable blindness among infants worldwide (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Blood levels of oxygen and their fluctuations have a prominent role in the physiopathology of ROP in preterm neonates by affecting endothelial growth factor secretion. Coincidence of other morbidities such as respiratory failure, sepsis, poor nutrition and weight gain, and blood sugar fluctuations could exacerbate the risk of ROP in premature infants (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). The incidence of ROP is constantly increasing as more immature infants survive due to the improvement of neonatal care (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). Laser photocoagulation is currently the gold standard treatment for ROP but might restrict the visual field and contribute to myopia development (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). The BEAT-ROP demonstrated a beneficial effect for intravitreal Bevacizumab (IVB) vs. laser in treating Zone I, Stage 3\u0026thinsp;+\u0026thinsp;ROP (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). IVB has also been used safely for the treatment of aggressive posterior ROP (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). IVB treatment could rapidly lead to the regression of vascular abnormality, especially in eyes with miotic pupils, and also lower the incidence of induced high myopia in type 1 ROP, compared with laser ablation. However, recurrence remains a major concern in the administration of IVB (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). Different risk factors have been related to ROP recurrence, such as Zone I ROP, early need for treatment, and low Apgar score (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). In this study, we aimed to retrospectively investigate children who received IVB as the primary treatment of ROP to compare some risk factors between those with and without ROP recurrence and complications after ROP recurrence treatment.\u003c/p\u003e"},{"header":"Materials and method","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003ePatients and examinations:\u003c/h2\u003e \u003cp\u003eThis retrospective study investigated ROP recurrence risk factors among those who received IVB because of ROP type 1 during one year (September 2022 to September 2023) in Nikookari Hospital, Tabriz, Iran. This center is the referral ROP center in the northwest of Iran.\u003c/p\u003e \u003cp\u003eIn this study, 98 eyes of 49 infants with ROP who had received IVB injections as the primary treatment are included. The exclusion criteria were IVB complications such as endophthalmitis and cataract formation. We did not have any infants with exclusion criteria. All of the patients had regular follow up at scheduled times. Recurrence was defined as the redevelopment of plus disease, pathological new vessels, or elevated ridge following a complete regression of ROP after IVB injection. We compared the following risk factors between those with and without ROP recurrence: birth gestational age (weeks), postmenstrual age at IVB injection time (days), IVB injection gap period from birth (days), birth body weight (grams), any history of oxygen therapy after IVB injection, mean oxygen therapy period after IVB injection (days), ROP Stage, and diet (breastfeeding, powdered milk or mixed). A retina subspecialist examined all infants after pupillary dilation with topical tropicamide 0.8%. Indirect funduscopy by pan-retinal Volk lens (Mentor, Ohio 44060, US) was used for retinal examination. The same physician examined all patients during follow-up visits and the IVB injections. The IVB was injected on the same day of the examination for type 1 ROP.\u003c/p\u003e \u003cp\u003eAny ROP stage with plus disease in zone I, stage 3 ROP in zone I, and stage 2 or 3 ROP with plus disease in zone II are classified as type 1 ROP (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). In the case of ROP recurrence, the same physician applied retinal laser photocoagulation.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eIntravitreal injections:\u003c/h2\u003e \u003cp\u003eThe parents of all the neonates were informed about the IVB injection procedure and its possible side effects and complications. Then, written informed consent forms were taken before the procedure. All the neonates received intravitreal Bevacizumab (0.25 mg/0.01 mL) injection with a gauge-30 needle inserted at 0.5 to 1.0 mm distance from limbus supra-temporally under sedation and topical anesthesia.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eEthical considerations:\u003c/h2\u003e \u003cp\u003eThe study was approved by the medical research ethics committee at Tabriz University of the Medical Sciences with an approval code of IR.TBZMED.REC.1401.800. As mentioned above, all the procedures were applied after the parents' informed consent was taken.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis:\u003c/h2\u003e \u003cp\u003eAll the statistical analysis in this study was performed using IBM SPSS Statistics 27.0, and the Kaplan-Meier curves were depicted by GraphPad Prism 10.0. The distribution of the quantitative data was examined by the Kolmogorov-Smirnov test and histograms. The normally distributed variables were analyzed by parametric tests such as the student's T-test, and the other data were analyzed by non-parametric tests such as Mann-Whitney U. The categorical variables were analyzed by Chi-square and Fisher-Freeman-Halton Exact Test. The alpha error in this study is considered 0.05, and p-values lower than 0.05 are considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eRecurrence rate and ROP severity:\u003c/h2\u003e \u003cp\u003e98 eyes of 49 infants with ROP who had received intravitreal Bevacizumab are included in our study. 55.1% of the ROP cases had APROP, and 44.9% had Stage III Plus ROP in Zone II. Despite the intravitreal injection, the ROP recurred in 13 eyes (13.26%) of 8 infants. The mean period between the IVB injection and the ROP recurrence was 8.08 (95%CI:5.32\u0026ndash;10.83) weeks. Figure\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the Kaplan-Meier curve of ROP recurrence after IVB injection. All the eyes with ROP recurrence received laser photocoagulation therapy, and 12 achieved anatomic improvements and ROP regression without complications. However, in one eye, macular dragging happened after laser therapy and ROP regression.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e76.9% of the infants with ROP recurrence had APROP before IVB injection; on the other hand, the prevalence of the APROP in the infants with complete ROP regression was 51.7%. Although the recurrence rate in the APROP group was 18.51% compared to 6.81% in the zone II ROPs, this difference was not statistically significant regarding the Chi-Square test (p-value\u0026thinsp;=\u0026thinsp;0.089). The remaining infants in both groups had Stage III Plus ROP in Zone II.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eGestational age and birth body weight:\u003c/h2\u003e \u003cp\u003eThe median gestational age of the infants with the ROP recurrence was 26 (the interquartile range (IQR): 26.00\u0026ndash;29.00) weeks at birth. It was 29 (IQR: 27.25-30.00) weeks for the infants without the ROP recurrence. According to the Independent-Samples Mann-Whitney U Test, the two groups have no statistically significant difference (p-value\u0026thinsp;=\u0026thinsp;0.072). On the other hand, the ROP recurrence group received the IVB injection at the median postmenstrual age of 232 (IQR: 229.50-244.50) days compared to 251 (IQR: 245.00-257.00) days in the regressed eyes, which is a statistically significant difference (p-value\u0026thinsp;=\u0026thinsp;0.001). The ROP recurrence cases received the IVB injection in younger gestational ages compared to the complete regression cases. Also, when the time gap between the birth and the IVB injection was compared, results showed a significantly shorter gap period for the ROP recurrence cases. Completely regressed ROP cases received the IVB injection in a median of 50 (IQR: 40.00\u0026ndash;60.00) days from birth, while the recurrence cases received 30 (IQR: 30.00-58.50) days after birth (p-value\u0026thinsp;=\u0026thinsp;0.044).\u003c/p\u003e \u003cp\u003eIn addition, the two groups significantly differed regarding the birth body weight. The median weight for infants with the ROP recurrence was 1000 (IQR: 732\u0026ndash;1000) grams versus 1100 (IQR: 1000\u0026ndash;1350) grams in the other group (p-value\u0026thinsp;=\u0026thinsp;0.002). The infants who achieved the ROP regression without recurrence after the IVB injection had higher birth body weights.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eSupplemental oxygen therapy:\u003c/h2\u003e \u003cp\u003e10.58% of completely regressed ROP cases needed supplement oxygen therapy after the IVB injection compared to 69.23% of those in the ROP recurrence group. The difference between the two groups is statistically significant (p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001). The odds ratio for supplemental oxygen therapy after IVB injection is 19.0 (95%CI: 4.8\u0026ndash;74.4). While the prevalence of supplemental oxygen therapy was higher in the ROP recurrence group, there was also a significant difference in the mean oxygen therapy period between infants who received oxygen in the two groups (p-value\u0026thinsp;=\u0026thinsp;0.006). The mean period of oxygen therapy after the IVB injection was 9.0 (95%CI: 6.5\u0026ndash;11.4) days in the ROP recurrence cases and 5.0 (95%CI: 5.00\u0026ndash;5.00) in the complete regression group. The ROP recurrence cases, on average, received supplemental oxygen for 4.0 (95%CI: 1.5\u0026ndash;6.4) days more than the other group after the IVB injection. Figure\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e shows the Kaplan-Meier curve of ROP recurrence in two groups regarding the need for supplemental oxygen therapy after IVB injection.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eDiet:\u003c/h2\u003e \u003cp\u003eThe two groups had no significant difference in the infants' diet. 51.8% of wholly regressed ROPs received a combination of maternal and powdered milk, and 61.6% in the ROP recurrence group had the same diet (p-value\u0026thinsp;=\u0026thinsp;0.097). Neither the maternal nor powdered milk was associated with the ROP recurrence (p-value\u0026thinsp;=\u0026thinsp;0.321 and p-value\u0026thinsp;=\u0026thinsp;0.064, respectively). The ocular and demographic characteristics of the infants are available in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e in more detail.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eOcular and demographic characteristics of infants with ROP in two groups of complete regression and recurrence after IVB injection. T: Students' T-test, M: Mann-Whitney U, C: Chi-square, F: Fisher-Freeman-Halton Exact Test\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eROP Recurrence (n:13)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eROP Regression (n:85)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBirth gestational age (weeks)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26 (IQR: 26.00\u0026ndash;29.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29 (IQR: 27.25-30.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.072\u003csup\u003eM\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePostmenstrual age at IVB injection (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e232\u003c/p\u003e \u003cp\u003e(IQR: 229.50-244.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e251\u003c/p\u003e \u003cp\u003e(IQR: 245.00-257.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.001\u003c/b\u003e\u003csup\u003e\u003cb\u003eM\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eIVB injection gap period from birth (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30 (IQR: 30.00-58.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50 (IQR: 40.00\u0026ndash;60.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.044\u003c/b\u003e\u003csup\u003e\u003cb\u003eM\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBirth body weight (grams)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1000 (IQR: 732\u0026ndash;1000)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1100 (IQR: 1000\u0026ndash;1350)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.002\u003c/b\u003e\u003csup\u003e\u003cb\u003eM\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eOxygen therapy after IVB injection (n)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (69.23%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (10.58%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003csup\u003e\u003cb\u003eC\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eMean oxygen therapy period (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9.0 (95%CI: 6.5\u0026ndash;11.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.0 (95%CI: 5.00\u0026ndash;5.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.006\u003c/b\u003e\u003csup\u003e\u003cb\u003eT\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eStage (n)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAPROP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e44 (51.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.089\u003csup\u003eC\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZ(II)\u003c/p\u003e \u003cp\u003eS(III) plus\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e41 (48.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eDiet (n)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMaternal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20 (23.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003e0.097\u003csup\u003eF\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePowdered\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (38.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e21 (24.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMixed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (61.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e44 (51.8%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe physiological process of human embryonic retinal vascularization consists of vasculogenesis and angiogenesis. Through vasculogenesis, blood vessels are generated by the endothelial cells' differentiation from their progenitors. This process takes place between the 12th and 21st week of gestational age. Angiogenesis is the process that leads to the formation of the superficial plexus. During angiogenesis, the retinal capillary plexus is generated from the optic nerve retinal vessels, branched and elongated towards the peripheral retina. These new vessels reach the nasal and temporal periphery at 32 and 36\u0026ndash;40 weeks of gestational age, respectively (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eROP is a vasoproliferative disease caused by Vascular endothelial growth factor (VEGF) production due to retinal ischemia. IVB has been suggested as a treatment for ROP in the presence of aggressive posterior ROP, miotic pupil, or media opacity. Its advantages over laser therapy are availability, a simple technique of injection, and the preservation of the visual field. It has some disadvantages compared to laser therapy, including endophthalmitis, cataract formation, and a higher recurrence rate, especially after a more extended period (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). The major risk factors for ROP are prematurity (low gestational age and birth weight) and supplemental Oxygen therapy. More advanced neonatal care and specialized hospitals could reduce the ROP incidence rate, as small hospital studies compared with tertiary referral hospitals approve of it (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). When the gestational age is lower, the area of the ischemic retina is more extensive. As a result, the concentration of VEGF in the vitreous cavity would be higher, so the probability of type 1 ROP requiring treatment would be higher (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eROP recurrence is the redevelopment of plus disease, pathological new vessels, or elevated ridge following a complete regression of ROP following treatment (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). The recurrence rate in our study was 13.26%, which was relatively lower than in similar studies. A study comparing laser photocoagulation and intravitreal Ranibizumab injection showed an 18.3% recurrence rate in the Ranibizumab group. However, the mean interval between the injection and recurrence was similar (8.08 vs. 9.3 weeks) (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). On the other hand, another study showed a much lower recurrence rate (4.04%) after IVB injection in ROP cases. This lower recurrence rate might be related to the lower prevalence of Zone I ROP (21.6%) in the sample size (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIn our study, low birth weight was a risk factor for ROP recurrence. However, lower gestational age was not statistically significant (the median gestational age was 26 weeks in the group with ROP recurrence compared to 29 weeks in those without recurrence). This statistically insignificant difference can be due to the study's low recurrence rate and small sample size. Most studies have confirmed that lower gestational age and weight are risk factors for ROP and its recurrence (\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). However, logistic regression in a large study revealed that the Gestational age (GA) and Birth weight are not independent risk factors for the recurrence after Ranibizumab (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). The possible relationship between lower GA and Birth weight with ROP recurrence can be explained by more immature retinal vasculature, which leads to a larger area of ischemic retina, as mentioned above. Although GA was not a statistically significant risk factor for recurrence in our study, the lower postmenstrual age at IVB injection was associated with ROP recurrence. The Iwahashi et al showed a higher rate of recurrence in neonates receiving anti-VEGF threpy earlier than 35-week of postmenstrual age (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSupplemental oxygen therapy has been described as a risk factor for ROP development (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). In this study, we investigated the role of oxygen therapy after IVB injection. The number of children who received Oxygen after IVB injection and the duration of oxygen therapy were higher in the group with ROP recurrence. Similar to our study, the study by Ling et al. showed that oxygen therapy after IVB injection or intravitreal ranibizumab injection was associated with higher ROP relapse (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). It has been declared that O\u003csub\u003e2\u003c/sub\u003e saturation fluctuations are more related to higher oxidative stress and ROP occurrence than steady prolonged hyperoxia (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). So, infants who need oxygen therapy even after IVB injection may have more unstable respiratory and metabolic conditions, leading to more oxidative stress, which induces ROP recurrence.\u003c/p\u003e \u003cp\u003eBesides, we have to take into account that these children are hospitalized due to respiratory problems or other systemic conditions that can worsen retinal hypoxia or ischemia. Premature infants are more prone to other exacerbating conditions, such as infections, and may have more severe forms of retinopathy due to the lower compliance of anti-oxidant metabolic pathways (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). With lower oxygen saturation, the rate of mortality increases; with higher oxygen saturation, the rate of ROP increases (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e). So, it is hard to determine which oxygen saturation level suits these patients.\u003c/p\u003e \u003cp\u003eSimilar to Ling et al. study (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e), those infants who received IVB injection sooner after birth had a higher probability of ROP recurrence (the median of 30 days in those with ROP recurrence versus 50 days in those without relapse). This difference shows that the imbalance between angiogenic and anti-angiogenic agents occurs at a shorter period in these children, leading to the development of type 1 ROP. So, the probability of reaching this unbalanced state in the future after IVB injection is higher among these infants.\u003c/p\u003e \u003cp\u003eRecent studies hypothesized that lower Insulin-like growth factor-1 (IGF-1) levels at birth could be related to the ROP occurrence, and infants' nutrition could alter the IGF-1 levels (\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). In addition, a systematic review demonstrated a protective role for human milk intake against the ROP and its severe forms (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). We aimed to find any possible association between the infants' diet type and ROP recurrence, which is not addressed well in the literature; however, we did not find any significant relationship.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eROP is the most common cause of visual impairment among infants. So, the most critical point in ROP management is preventing severe forms (type 1) that require treatment by improving neonatal care and well-established ophthalmic screenings for preterm infants. Although IVB injection could be a suitable replacement for laser photocoagulation in the ROP treatment, the recurrence after treatment should be considered, and infants should be monitored closely, especially until ten weeks, when most recurrences occur. Infants with lower Birth weight, an earlier need for IVB injection, and those who need supplemental oxygen for a more extended period should be considered at high risk for recurrence. Besides, a collaboration between neonatologists and ophthalmologists could lower the recurrence rate by minimizing post-IVB oxygen therapy.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eROP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eRetinopathy of prematurity\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIVB\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eIntravitreal bevacizumab injection\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAPROP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eAggressive posterior retinopathy of prematurity\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eVEGF\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eVascular endothelial growth factor\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGestational age\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIGF-1\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eInsulin-like growth factor-1\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor information:\u003c/h2\u003e \u003cp\u003eAuthors and Affiliations.\u003c/p\u003e \u003cp\u003eDepartment of Ophthalmology, Nikookari Eye Hospital,Tabriz University of Medical Sciences, Tabriz, Iran:\u003c/p\u003e \u003cp\u003eAmir Eftekhari Milani, Amin Arasteh, Zahra Saeedi-Maleki, Fariborz Brumandpur\u003c/p\u003e \u003cp\u003eStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran:\u003c/p\u003e \u003cp\u003eAmin Arasteh\u003c/p\u003e \u003ch2\u003eEthics approval and consent to participate\u003c/h2\u003e \u003cp\u003eThe study was approved by the medical research ethics committee at Tabriz University of the Medical Sciences with an approval code of IR.TBZMED.REC.1401.800. All the procedures were applied after the parents' informed consent was taken. The study was conducted in accordance with the Declaration of Helsinki, good clinical practices, and relevant regulatory guidelines.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eConsent for publication:\u003c/strong\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCompeting interests:\u003c/strong\u003e \u003cp\u003eThe authors declare that they have no competing interests\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding:\u003c/h2\u003e \u003cp\u003eNo fund\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eExperimental design: AEM, FB.Data collection and analysis: AEM, AA.Manuscript drafting and revision: FB, ZSM, AAAll authors reviewed the manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgments:\u003c/h2\u003e \u003cp\u003eNot applicable\u003c/p\u003e\u003ch2\u003eAvailability of data and materials:\u003c/h2\u003e \u003cp\u003eThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSoll RF. Treatment of Retinopathy of Prematurity: Moving Forward With Uncertainty. JAMA. 2022;328(4):332\u0026ndash;3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(1):35\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePertl L, Steinwender G, Mayer C, Hausberger S, P\u0026ouml;schl EM, Wackernagel W, et al. A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE. 2015;10(6):e0129383.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcLoone E, O'Keefe M, McLoone S, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44(3):170\u0026ndash;3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaraca C, Oner AO, Mirza E, Polat OA, Sahiner M. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131(8):1099\u0026ndash;101.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal Bevacizumab for stage 3\u0026thinsp;+\u0026thinsp;retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEftekhari Milani A, Hassanpoor N, Mousavi Mirkala M, Taheri A, Golizade A, Niyousha MR. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity. Int Ophthalmol. 2020;40(2):477\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFadakar K, Mehrabi Bahar M, Riazi-Esfahani H, Azarkish A, Farahani AD, Heidari M, et al. Intravitreal Bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence. Int Ophthalmol. 2022;42(7):2017\u0026ndash;28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLing KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina Phila Pa. 2020;40(9):1793\u0026ndash;803.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of Prematurity: A Review of Risk Factors and their Clinical Significance. Surv Ophthalmol. 2018;63(5):618\u0026ndash;37.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSonmez K, Drenser KA, Capone A, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophtha. 2008;115(6):1065\u0026ndash;70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMart\u0026iacute;nez-Castellanos MA, Gonz\u0026aacute;lez-H Le\u0026oacute;n A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):767\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCao JK, Han T, Tang HY, Zhang S, Wang ZH, Feng ZC, et al. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmol. 2023;23(1):137.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, et al. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina. 2021;41(11):2261.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, et al. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors. Invest Ophthalmol Vis Sci. 2017;58(3):1719\u0026ndash;25.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFevereiro-Martins M, Marques-Neves C, Guimar\u0026atilde;es H, Bicho M. Retinopathy of prematurity: A review of pathophysiology and signaling pathways. Surv Ophthalmol. 2023;68(2):175\u0026ndash;210.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHartnett ME, Lane RH. Effects of Oxygen on the development and severity of retinopathy of prematurity. J AAPOS. 2013;17(3):229\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoods J, Biswas S. Retinopathy of prematurity: from oxygen management to molecular manipulation. Mol Cell Pediatr. 2023;10(1):12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBharwani SK, Green BF, Pezzullo JC, Bharwani SS, Bharwani SS, Dhanireddy R. Systematic review and meta-analysis of human milk intake and retinopathy of prematurity: a significant update. J Perinatol. 2016;36(11):913\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-ophthalmology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"boph","sideBox":"Learn more about [BMC Ophthalmology](http://bmcophthalmol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/boph","title":"BMC Ophthalmology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Bevacizumab, Recurrence, Retinopathy of prematurity, Risk factors","lastPublishedDoi":"10.21203/rs.3.rs-3979739/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3979739/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eRetinopathy of prematurity (ROP) is a proliferative disorder of the developing retina. Intravitreal bevacizumab injection (IVB) is an emerging treatment for ROP is one of the treatments for ROP has many benefits. The present study aimed to determine and evaluate the risk factors for ROP recurrence following IVB injection.\u003c/p\u003e\u003ch2\u003eMaterials and method\u003c/h2\u003e \u003cp\u003eIn this retrospective study, 98 eyes of 49 infants with ROP who had received IVB injections as the primary treatment for type 1 ROP are included.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eFifty-four eyes (55.1%) had Aggressive posterior retinopathy of prematurity (APROP), and forty-four (44.9%) had Stage III Plus ROP in Zone II. ROP recurred in 13 eyes (13.26%) of 8 infants. The mean period between IVB and the ROP recurrence was 8.08 (95% CI:5.32\u0026ndash;10.83) weeks. The infants who had ROP recurrence had lower birth weight (P value\u0026thinsp;=\u0026thinsp;0.002), lower postmenstrual age at IVB injection (P value\u0026thinsp;=\u0026thinsp;0.001), lower IVB injection gap period from birth (P value\u0026thinsp;=\u0026thinsp;0.044), higher oxygen therapy requirement rate after IVB injection (P value\u0026thinsp;\u0026lt;\u0026thinsp;0.001, OR:19.0) and higher oxygen therapy duration (P value\u0026thinsp;=\u0026thinsp;0.006). The ROP severity, gestational age at birth, and diet were not statistically different between the recurrence and complete regression groups. Out of 13 eyes treated with laser photocoagulation because of ROP relapse, macula dragging occurred in one eye, and all the cases met the complete regression.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eLow birth weight and oxygen therapy are the most important risk factors for ROP relapse, which requires meticulous oxygen treatment guidelines for premature infants.\u003c/p\u003e","manuscriptTitle":"Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-29 16:00:16","doi":"10.21203/rs.3.rs-3979739/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-05-15T02:25:02+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-05-09T17:07:39+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-05-07T05:33:23+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"318501445849689184400010962712123256327","date":"2024-05-01T01:40:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"238116900897098803300846098019559382523","date":"2024-04-30T20:33:47+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-04-30T09:25:11+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-02-27T08:43:05+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-02-27T06:36:43+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-02-27T06:01:08+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Ophthalmology","date":"2024-02-22T20:25:04+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-ophthalmology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"boph","sideBox":"Learn more about [BMC Ophthalmology](http://bmcophthalmol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/boph","title":"BMC Ophthalmology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5bf96b37-097e-4171-8d44-d5656f99a8a8","owner":[],"postedDate":"February 29th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2024-06-17T05:53:10+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-29 16:00:16","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3979739","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3979739","identity":"rs-3979739","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}